Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …
The impact of endometriosis on cardiovascular and cerebrovascular diseases: A Mendelian randomization study.
Endometriosis has been linked to several systemic complications, including cardiovascular disease (CVD), atrial fibrillation (AF), heart failure (HF), hypertension, stroke, and ischemic stroke. The potential causal relationship between endometriosis and …